[Effects of PGI2 analogue (CS-570) in patients with acute myocardial infarction: dose response effects on cardiovascular hemodynamics, plasma prostanoids, catecholamines and cyclic nucleotides].
D000368:Aged; D000369:Aged, 80 and over; D002395:Catecholamines / Q000097:blood*; D000242:Cyclic AMP / Q000097:blood; D006152:Cyclic GMP / Q000097:blood; D004305:Dose-Response Relationship, Drug; D011464:Epoprostenol / Q000008:administration & dosage / Q000627:therapeutic use* / Q000031:analogs & derivatives; D005227:Fatty Acids / Q000097:blood*; D005260:Female; D006439:Hemodynamics; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D011466:Prostanoic Acids / Q000097:blood*
D002395:Catecholamines; D005227:Fatty Acids; D011466:Prostanoic Acids; C038991:R 59274; D011464:Epoprostenol; D000242:Cyclic AMP; D006152:Cyclic GMP